|
|
||||||||
TRANSLATIONAL PHYSIOLOGY
Division of Endocrinology, Metabolism and Lipid Research, Division of Infectious Diseases, Departments of Internal Medicine, Cell Biology and Physiology, Washington University Medical School, St. Louis, Missouri 63110
Submitted 24 January 2003 ; accepted in final form 24 June 2003
Protease inhibitor-based highly active antiretroviral therapy (PI-HAART) has been implicated in dyslipidemia, peripheral insulin resistance, and abnormal adipose tissue deposition in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome, or AIDS. In vitro evidence indicates that some PIs reduce adipocyte lipoprotein (LPL) and hepatic lipase (HL) expression and activities. We examined whether LPL and HL activities are reduced in HIV-infected patients with dyslipidemia. Fasting serum lipids, glucoregulatory hormones, and postheparin LPL and HL activities, as well as whole body and regional adiposity, were measured in 19 HIV-seronegative controls, 9 HIV+ patients naive to all anti-HIV medications, 9 HIV+ patients naive to PIs, 9 HIV+ patients with prior PI experience but not currently receiving PIs, and 47 HIV+ patients receiving PI-HAART. The PI-HAART group had low LPL and HL activities. However, multiple linear regression analysis indicated that low postheparin LPL activity contributed only partially to HIV-dyslipidemia. Central adiposity and high C-peptide levels (an indicator of high insulin secretion) were stronger predictors of HIV-dyslipidemia. Low LPL and HL activities, by themselves, were insufficient to explain HIV-dyslipidemia because the PI-naive group had low LPL and HL activities but had normal adiposity, C-peptide levels, and serum lipid and lipoprotein levels. HDL-cholesterol was lower in PI-HAART and PI-naive groups than seronegative controls and was directly associated with LPL activity. These findings suggest that HIV-dyslipidemia is mediated primarily by factors that influence triglyceride and lipoprotein synthesis (e.g., central adiposity and hyperinsulinemia) and mediated only partially by factors that influence triglyceride clearance (e.g., lipase activity).
acquired immunodeficiency syndrome; human immunodeficiency virus; metabolic complications; insulin resistance; central obesity; aspartyl protease inhibitors; lipoprotein lipase; magnetic resonance imaging
This article has been cited by other articles:
![]() |
W. T. Cade, D. N. Reeds, B. Mittendorfer, B. W. Patterson, W. G. Powderly, S. Klein, and K. E. Yarasheski Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E812 - E819. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Reeds, W. T. Cade, B. W. Patterson, W. G. Powderly, S. Klein, and K. E. Yarasheski Whole-Body Proteolysis Rate Is Elevated in HIV-Associated Insulin Resistance. Diabetes, October 1, 2006; 55(10): 2849 - 2855. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |